Evaxion Biotech (EVAX) Price & Analysis

Compare

358 Followers

EVAX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.20 - $17.75

Previous CloseN/A

Volume99.85K

Average Volume (3M)109.82K

Market Cap

$17.37M

Enterprise Value$10.03M

Total Cash (Recent Filing)$4.58M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.75

Next Earnings

Nov 11, 2025

EPS Estimate

-0.59

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding6,316,572

10 Day Avg. Volume111,784

30 Day Avg. Volume109,820

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.58

Enterprise Value/Revenue3.04

Enterprise Value/Gross Profit3.04

Enterprise Value/Ebitda-1.09

Forecast

1Y Price Target

$10.00

Price Target Upside263.64% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical TrialsContinued success with the ongoing Phase 2 study with EVX-01 as a therapy for metastatic melanoma has led to the extension of the trial, showing confidence in the study's potential.

Financial StabilityThe potential cash infusion from Merck's option exercise could extend the company's cash runway into 2027, providing financial stability.

Strategic PartnershipsMerck increased its stake in Evaxion to nearly 20%, indicating strong confidence in the company's potential.

Bears Say

Financial PerformanceEvaxion reported total revenues of $3.3M, which fell short of the consensus estimate of $4.5M.

Revenue And EarningsEvaxion reported no revenues with a net loss of $0.02 per diluted share, compared to consensus estimated no revenues and net loss of $0.58 per diluted share.

Risks And ChallengesRisks to the Buy rating include partnership, technology, clinical, regulatory, commercial, legal and intellectual property, competition, and dilution.

Evaxion Biotech News

Evaxion Biotech reports Q2 EPS (2c) vs (12c) last year

Reports Q2 revenue $37,000 vs $154,000 last year. “We maintain a strong operational momentum as we track towards...

20d ago

EVAX

Evaxion Biotech A/S Adr Earnings Call: Strategic Growth Amid Challenges

Evaxion Biotech A/S Adr (($EVAX)) has held its Q2 earnings call. Read on for the main highlights of...

2d ago

EVAX

Evaxion Announces Conference Participation for H2 2025

Evaxion Biotech ( ($EVAX) ) has shared an announcement. On August 27, 2025, Evaxion A/S announced its participation...

7d ago

EVAX

Evaxion Biotech: Promising Developments and Strategic Collaborations Support Buy Rating with $14 Price Target

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Evaxion Biotech and keeping the price target...

19d ago

EVAX

Evaxion Biotech Reports Q2 2025 Financial Results

Evaxion Biotech A/S Adr ( ($EVAX) ) has released its Q2 earnings. Here is a breakdown of the...

19d ago

EVAX

Evaxion A/S Reports Q2 2025 Financials and Strategic Progress

Evaxion Biotech ( ($EVAX) ) has shared an announcement. On August 14, 2025, Evaxion A/S announced a business...

20d ago

EVAX

Evaxion Biotech Reports Q2 2025 Financial Results with Notable Losses

Evaxion Biotech ( ($EVAX) ) has provided an announcement. Evaxion Biotech A/S reported its financial results for the...

20d ago

EVAX

Evaxion A/S to Present Q2 2025 Financial Results and Business Update

Evaxion Biotech ( ($EVAX) ) just unveiled an update. On August 11, 2025, Evaxion A/S announced that it...

23d ago

EVAX

Evaxion to Present Promising Phase 2 Results of Cancer Vaccine at ESMO 2025

Evaxion Biotech ( ($EVAX) ) has issued an update. On July 25, 2025, Evaxion A/S announced that it...

1M ago

EVAX

Evaxion to present two-year clinical efficacy data from Phase 2 EVX-01 trial

Evaxion will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at...

1M ago

EVAX

Evaxion Biotech Finalizes Debt Settlement with EIB

Evaxion Biotech ( ($EVAX) ) has provided an announcement. On July 11, 2025, Evaxion Biotech finalized a debt...

2M ago

EVAX

Evaxion Converts Debt to Equity in EIB Agreement

The latest update is out from Evaxion Biotech ( ($EVAX) ). On July 11, 2025, Evaxion A/S finalized...

2M ago

EVAX

Evaxion Biotech finalizes agreement with EIB to convert debt into equity

Evaxion has finalized its agreement with the European Investment Bank to convert debt into equity. EIB will convert...

2M ago

EVAX

Evaxion Biotech announces Kanstrup has stepped down as CEO

Evaxion announces several key executive management changes to optimize value from its proprietary AI-Immunology platform and pipeline. Christian...

2M ago

EVAX

EVAX FAQ

What was Evaxion Biotech’s price range in the past 12 months?

Evaxion Biotech lowest stock price was $1.20 and its highest was $17.75 in the past 12 months.

What is Evaxion Biotech’s market cap?

Evaxion Biotech’s market cap is $17.37M.

When is Evaxion Biotech’s upcoming earnings report date?

Evaxion Biotech’s upcoming earnings report date is Nov 11, 2025 which is in 69 days.

How were Evaxion Biotech’s earnings last quarter?

Evaxion Biotech released its earnings results on Aug 14, 2025. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.58 by $0.56.

Is Evaxion Biotech overvalued?

According to Wall Street analysts Evaxion Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Evaxion Biotech pay dividends?

Evaxion Biotech does not currently pay dividends.

What is Evaxion Biotech’s EPS estimate?

Evaxion Biotech’s EPS estimate is -0.59.

How many shares outstanding does Evaxion Biotech have?

Evaxion Biotech has 6,316,572 shares outstanding.

What happened to Evaxion Biotech’s price movement after its last earnings report?

Evaxion Biotech reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.58. Following the earnings report the stock price went down -5.921%.

Which hedge fund is a major shareholder of Evaxion Biotech?

Currently, no hedge funds are holding shares in EVAX

Company Description

Evaxion Biotech

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Evaxion Biotech (EVAX) Earnings & Revenues

Historic Earnings Reports

EVAX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant progress in partnerships, financial stability, and R&D developments, particularly with the MSD partnership and a grant from the Gates Foundation. However, there are challenges due to regulatory and market uncertainties, and limited disclosure on clinical data was noted.View all EVAX earnings summaries

EVAX Stock 12 Month Forecast

Average Price Target

$10.00

▲(263.64% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","19":"$19","4.75":"$4.75","9.5":"$9.5","14.25":"$14.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.75,9.5,14.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.61,3.486153846153846,4.362307692307692,5.2384615384615385,6.114615384615385,6.9907692307692315,7.866923076923078,8.743076923076924,9.61923076923077,10.495384615384616,11.371538461538462,12.247692307692308,13.123846153846154,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.61,3.1784615384615384,3.7469230769230766,4.315384615384615,4.883846153846154,5.452307692307692,6.020769230769231,6.589230769230769,7.157692307692308,7.726153846153846,8.294615384615385,8.863076923076923,9.43153846153846,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.61,2.8707692307692305,3.1315384615384616,3.3923076923076922,3.653076923076923,3.9138461538461535,4.174615384615384,4.435384615384615,4.696153846153846,4.9569230769230765,5.217692307692307,5.478461538461538,5.739230769230769,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.15,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.35,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.35,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.25,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.95,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.23,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.46,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.72,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >